← board
AMRX
Amneal Pharmaceuticals, LLCdistress 1/10 · well-funded / low risk$17.710%today-2% from 52w high
Cardiovascular 1
Lead: Open-angle Glaucoma · target Prostaglandin · est. market ~$6B (approx, global)
Revenue
$723M
Liquidity
$198M
Runway
—
Shares 1y
+2%
Price & events
+30.4% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.2%
1D
-1.8%
1W
+6.3%
1M
+40.0%
3M
+32.3%
6M
+119.5%
1Y
+138.4%
2Y
+266.8%
5Y
+263.0%
All
Overview
- Market Cap
- $5.65B
- Enterprise Value
- $8.02B
- Volume
- 74.00K
- 52 Week Range
- $7.82 – $18.10
- Total Shares
- 319.02M
- Float Shares
- 178.38M
- Short %
- 3.62%
- % Held by Insiders
- 49.04%
- % Held by Institutions
- 52.24%
- RVOL
- 0.03x
- Beta
- 1.26
Pipeline stages · 1 programs
Bimatoprost Ophthalmic Solution, 0.01%, LUMIGAN® (bimatoprost ophthalmic solution) 0.01%Prostaglandin
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2025-03-01 | Phase 1 | Bimatoprost Ophthalmic Solution, 0.01%, LUMIGAN® (bimatoprost ophthalmic solution) 0.01% | Open-angle Glaucoma, Ocular Hypertension | 240 | recruiting |
Catalyst news & presentations · 3
- 2026-07-30Estimated 45%earningsEarningsEarnings releaseyahoo
- 2026-04-21partnershipAcquisition of 100% of Kashiv BioSciences for $375M cash plus shares, with up to $350M regulatory milestone payments.SEC 8-K
- 2024-10-01partnershipCollaboration with Metsera to develop and supply next-generation medicines for obesity and metabolic diseasesSEC 8-K
Approved drugs (11)
- OZILTUSDENOSUMAB-MOBZ2025 · Prescription
- BONCRESADENOSUMAB-MOBZ2025 · Prescription
- BREKIYA (AUTOINJECTOR)DIHYDROERGOTAMINE MESYLATE2025 · Prescription
- PYRIDOSTIGMINE BROMIDEPYRIDOSTIGMINE BROMIDE2024 · Discontinued
- POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDEPOTASSIUM PHOSPHATE, DIBASIC2024 · Prescription
- ALYMSYSBEVACIZUMAB-MALY2022 · Prescription
- ONGENTYSOPICAPONE2020 · Prescription
- TIGECYCLINETIGECYCLINE2018 · Prescription
- ZOMIGZOLMITRIPTAN2003 · Prescription
- ACTIVELLAESTRADIOL1998 · Prescription
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $18 (+3% upside) · 4 analysts
- 2026-07-15UBSBuy
- 2026-05-20BarclaysOverweight
- 2026-04-17UBSBuy
- 2026-03-02Truist SecuritiesBuy
- 2025-12-09BarclaysOverweight
- 2025-10-31Piper SandlerOverweight
Recent news
- 2026-07-22AMRX: Amneal Pharmaceuticals Inc - Ordinary Shares - Class A Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
- 2026-07-20Amneal: Kashiv Deal Fuels Biosimilar Growth, But Stock Already Prices In Optimism (AMRX) - Seeking Alpha
- 2026-07-19Amneal Pharmaceuticals (AMRX) Proxy filing Summary - Quartr
- 2026-07-18How First-Generic OMNIPAQUE Rivals At Amneal Pharmaceuticals (AMRX) Have Changed Its Investment Story - Sahm
- 2026-07-17Amneal receives FDA approval for additional iohexol strengths - Investing.com
- 2026-07-17Amneal Pharmaceuticals Receives FDA Approval for Additional Iohexol Injection Strengths and Vial Presentations - Quiver Quantitative
- 2026-07-17Amneal's FDA-approved contrast options give hospitals more vial choices - Stock Titan
- 2026-07-17Amneal Expands Iohexol Injection Portfolio with U.S. FDA Approval of Additional Strengths and Presentations - GlobeNewswire
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.